|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.01 / 0.10|
Bayer's takeover of Monsanto is expected to receive extra scrutiny out of fears the deal could prove detrimental for European farmers.
With Calyxt, perhaps you truly can have your cake and eat it too.
Delrahim can expect questions from committee members about questionable remarks President Trump made on the campaign trail.
Antitrust experts say DOJ and FTC will need to tune out the president's Twitter feed.
Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.
Einhorn picked up new positions in Syngenta and others.
Shares of the target rose after president-elect's team touted companies' offer to spend billions in R&D
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Jim Cramer says he doesn't think the Monsanto and Bayer merger will be approved by regulators.
The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.
AstraZeneca, Bayer, Eli Lilly and Merck are just a few of the names that may join a bidding war for the cancer drug maker, analysts say.
China National Chemical Corp. is making history with its nearly $44 billion deal to acquire Swiss agrichemical producer Syngenta.
The currently unloved chemical giant is poised to rebound on the strength of new leadership and internal streamlining.
Stocks may be cheaper in Europe than the U.S., but the political risk surrounding Greece doesn't bode well for the region, one strategist said.
Stocks pull back after early gains as investors sort through big batch of earnings
Stock futures climb following strong earnings globally; investors eye weekly jobless claims
Upbeat earnings, economic news gives world markets a lift; euro hits 11-week high
German chemical, pharmaceutical company Bayer says Q4 net income rose 44 percent
Pressure rises to stop antibiotics in agriculture; animals fed 70 percent of US antibiotics
Swiss fine Pfizer, Eli Lilly, Bayer $5.7M for price-fixing of erectile dysfunction drugs
Pharmaceutical cos. accept Ecuador's decision to produce low-cost versions of patented drugs
German drug, chemical company Bayer's Q3 net income falls 10 percent to euro249 million
Survey shows dip in German investor confidence amid mixed economic signals
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.